The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | MDM2 inhibition in AML: trial updates
The inhibition of MDM2 blocks the MDM2-p53 protein-protein interaction, allowing p53 to signal for apoptosis; however, there have been challenges with implementing this approach as a therapy. Here, Marina Konopleva, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the latest data regarding MDM2 inhibitor therapy for acute myeloid leukemia (AML); in combination with cytarabine (MIRROS; NCT02545283) or in combination with venetoclax (NCT02670044). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
